Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Mar 31, 2023
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-022199General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-229.69% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
-53.14% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
171.70% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
45.33% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-268.26% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
23.79% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
14.05% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.72%
- Current
- 0.00%
- Delta
- -0.72%
- Previous
- -140.39%
- Current
- -229.69%
- Delta
- -89.30%
- Previous
- 46.84%
- Current
- -53.14%
- Delta
- -99.98%
- Previous
- 25.82%
- Current
- 171.70%
- Delta
- 145.88%
- Previous
- 1.55%
- Current
- 45.33%
- Delta
- 43.78%
- Previous
- -188.98%
- Current
- -268.26%
- Delta
- -79.28%
- Previous
- 15.16%
- Current
- 23.79%
- Delta
- 8.63%
- Previous
- 11.11%
- Current
- 14.05%
- Delta
- 2.94%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA Fundamental State →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA Fundamental State →Transitioned To · RKDA CAPEX_INTENSITY_DECREASED →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA GROWTH_DECREASED →Transitioned To · RKDA INVENTORY_PRESSURE_INCREASED →Transitioned To · RKDA MARGIN_INCREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.